AU2001278699A1 - Inflammatory cytokine production inhibitors - Google Patents
Inflammatory cytokine production inhibitorsInfo
- Publication number
- AU2001278699A1 AU2001278699A1 AU2001278699A AU7869901A AU2001278699A1 AU 2001278699 A1 AU2001278699 A1 AU 2001278699A1 AU 2001278699 A AU2001278699 A AU 2001278699A AU 7869901 A AU7869901 A AU 7869901A AU 2001278699 A1 AU2001278699 A1 AU 2001278699A1
- Authority
- AU
- Australia
- Prior art keywords
- cytokine production
- inflammatory cytokine
- production inhibitors
- inhibitors
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000016396 cytokine production Effects 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000-239749 | 2000-08-08 | ||
| JP2000239749 | 2000-08-08 | ||
| PCT/JP2001/006814 WO2002011725A1 (en) | 2000-08-08 | 2001-08-08 | Inflammatory cytokine production inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001278699A1 true AU2001278699A1 (en) | 2002-02-18 |
Family
ID=18731237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001278699A Abandoned AU2001278699A1 (en) | 2000-08-08 | 2001-08-08 | Inflammatory cytokine production inhibitors |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2001278699A1 (en) |
| WO (1) | WO2002011725A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007004613A1 (en) | 2005-07-01 | 2007-01-11 | Ajinomoto Co., Inc. | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE AND TNF-α PRODUCTION INHIBITOR |
| US20070066512A1 (en) * | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
| CA2876540C (en) * | 2012-06-15 | 2022-11-29 | Conaris Research Institute Ag | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
| JP6895752B2 (en) | 2013-12-13 | 2021-06-30 | コナリス リサーチ インスティチュート アーゲー | A pharmaceutical composition comprising nicotinic acid and / or nicotinamide for beneficially affecting blood lipid levels by modifying the gut microbiota. |
| WO2015086838A2 (en) | 2013-12-13 | 2015-06-18 | Conaris Research Institute Ag | A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation |
| WO2022047182A1 (en) * | 2020-08-28 | 2022-03-03 | University Of Washington | High dose nicotinamide adenine dinucleotide (nad) precursor regimens for reduction of inflammation in human patients with preexisting inflammation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997010712A1 (en) * | 1995-09-19 | 1997-03-27 | Margolin Solomon B | Inhibition of tumor necrosis factor alpha |
-
2001
- 2001-08-08 AU AU2001278699A patent/AU2001278699A1/en not_active Abandoned
- 2001-08-08 WO PCT/JP2001/006814 patent/WO2002011725A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002011725A1 (en) | 2002-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002222683A1 (en) | Inflammatory cytokine release inhibitor | |
| AU2001258771A1 (en) | -secretase inhibitors | |
| AU2002220241A1 (en) | Parb inhibitors | |
| AU2001237041A1 (en) | Kinase inhibitors | |
| AU2001273040A1 (en) | Factor xa inhibitors | |
| AU2001260674A1 (en) | TNF-alpha production inhibitors | |
| AU2002211663A1 (en) | Nf-$g(k)b inhibitors | |
| AU2001293373A1 (en) | 2-guanidino-4-arylchinazolines as NHE-3 inhibitors | |
| AU2001239956A1 (en) | Solid bodies | |
| AU2001285750A1 (en) | Urokinase inhibitors | |
| AU5248800A (en) | Fading inhibitors | |
| AU2385601A (en) | Ethanol production | |
| AU2002222627A1 (en) | Tak1 inhibitors | |
| AU2001244562A1 (en) | Neovascularization inhibitors | |
| AU2002349621A1 (en) | Angiogenesis inhibitor | |
| AU2001278699A1 (en) | Inflammatory cytokine production inhibitors | |
| AU2001287725A1 (en) | Intermediates in cephalosporin production | |
| AU2002222628A1 (en) | Keratinocyte proliferation inhibitors | |
| AU2001283340A1 (en) | Factor viia inhibitors | |
| AU2003244347A1 (en) | Angiogenesis inhibitors | |
| AU2001233965A1 (en) | Novel cd23 inhibitors | |
| GB9814844D0 (en) | Cytokine production inhibitors | |
| AU2001268853A1 (en) | Biocatalyst inhibitors | |
| AU2003221324A1 (en) | Angiogenesis inhibitors | |
| AU2002253633A1 (en) | 20-hydroxyeicosatetraenoic acid production inhibitors |